Briefing: RFA-DK-26-007 – Type 1 Diabetes Biosamples & Data Collaborative Research

Research Focus

This R01 grant supports collaborative research using existing biosamples and clinical data from type 1 diabetes (T1D) studies to advance understanding of disease etiology and pathogenesis. The NIDDK seeks to accelerate prevention science by maximizing use of well-characterized participant cohorts—screened for genetic and phenotypic risk, often followed longitudinally before and after symptom onset—to identify biomarkers, disease mechanisms, and intermediate endpoints that could inform future prevention trials. Research should address T1D progression from autoimmunity through dysglycemia to clinical diagnosis, environmental triggers, immune responses to therapy, and beta-cell function decline. Multi-omics approaches, risk stratification models, and mechanistic studies of susceptibility, autoimmunity, and metabolic decline are encouraged. Eligible sample sources include the Diabetes Prevention Type 1 (DPT-1) trial, Type 1 Diabetes TrialNet (including Pathway To Prevention), TEDDY (Environmental Determinants of Diabetes in the Young), and the NIDDK Central Repository.

At a Glance

• Who can apply: Collaborative research teams with documented access to samples from eligible T1D clinical studies/consortia; access approval letter required with application.
• Funding & project length: $5.5 million committed per fiscal year (FY 2026, FY 2027); 3–4 awards anticipated per year; project duration not stated.
• Award mechanism: R01 Research Project Grant; clinical trials with efficacy endpoints not allowed.
• Key dates: Open May 26, 2025; applications due June 26, 2025 and March 6, 2026; earliest start April 2026 and December 2026; expires March 9, 2026.
• Best fit for: Biomedical researchers (immunology, genetics, metabolomics, epidemiology) studying T1D mechanisms using secondary analysis of prospective cohort data; cross-sectional and longitudinal observational designs preferred.